A new trading day began on Friday, with Immuneering Corp (NASDAQ: IMRX) stock price down -4.63% from the previous day of trading, before settling in for the closing price of $1.08. IMRX’s price has ranged from $1.05 to $10.25 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -43.59%. Meanwhile, its annual earnings per share averaged -2.39%. With a float of $21.00 million, this company’s outstanding shares have now reached $29.27 million.
Let’s determine the extent of company efficiency that accounts for 68 employees. In terms of profitability, gross margin is 100.79%, operating margin of 64.04%, and the pretax margin is 59.38%.
Immuneering Corp (IMRX) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Immuneering Corp is 29.16%, while institutional ownership is 38.11%. The most recent insider transaction that took place on Apr 01 ’24, was worth 1,160,181. In this transaction 10% Owner of this company sold 400,000 shares at a rate of $2.90, taking the stock ownership to the 2,895,273 shares. Before that another transaction happened on Mar 22 ’24, when Company’s Director bought 2,900 for $2.55, making the entire transaction worth $7,385. This insider now owns 2,900 shares in total.
Immuneering Corp (IMRX) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -2.39% per share during the next fiscal year.
Immuneering Corp (NASDAQ: IMRX) Trading Performance Indicators
Here are Immuneering Corp’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 9.39.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.91, a number that is poised to hit -0.55 in the next quarter and is forecasted to reach -1.52 in one year’s time.
Technical Analysis of Immuneering Corp (IMRX)
Looking closely at Immuneering Corp (NASDAQ: IMRX), its last 5-days average volume was 0.49 million, which is a drop from its year-to-date volume of 0.93 million. As of the previous 9 days, the stock’s Stochastic%D was 6.12%. Additionally, its Average True Range was 0.13.
During the past 100 days, Immuneering Corp’s (IMRX) raw stochastic average was set at 1.40%, which indicates a significant decrease from 3.90% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 109.42% in the past 14 days, which was higher than the 94.51% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.2713, while its 200-day Moving Average is $3.8626. However, in the short run, Immuneering Corp’s stock first resistance to watch stands at $1.0733. Second resistance stands at $1.1167. The third major resistance level sits at $1.1533. If the price goes on to break the first support level at $0.9933, it is likely to go to the next support level at $0.9567. Should the price break the second support level, the third support level stands at $0.9133.
Immuneering Corp (NASDAQ: IMRX) Key Stats
With a market capitalization of 30.54 million, the company has a total of 29,653K Shares Outstanding. Currently, annual sales are 0 K while annual income is -53,470 K. The company’s previous quarter sales were 0 K while its latest quarter income was -14,080 K.
